[go: up one dir, main page]

MX2018015985A - Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol. - Google Patents

Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.

Info

Publication number
MX2018015985A
MX2018015985A MX2018015985A MX2018015985A MX2018015985A MX 2018015985 A MX2018015985 A MX 2018015985A MX 2018015985 A MX2018015985 A MX 2018015985A MX 2018015985 A MX2018015985 A MX 2018015985A MX 2018015985 A MX2018015985 A MX 2018015985A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
alcohol use
devices
Prior art date
Application number
MX2018015985A
Other languages
English (en)
Inventor
Crystal Roger
Agrawal Arvind
T Maggio Edward
Original Assignee
Opiant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opiant Pharmaceuticals Inc filed Critical Opiant Pharmaceuticals Inc
Publication of MX2018015985A publication Critical patent/MX2018015985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan productos farmacológicos adaptados para administración nasal, que comprenden un dispositivo pre-preparado lleno de una composición farmacéutica que comprende naltrexona. También se proporciona formulaciones y métodos para tratar el trastorno por consumo de alcohol y afecciones relacionadas con los medicamentos.
MX2018015985A 2016-06-24 2017-06-26 Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol. MX2018015985A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354465P 2016-06-24 2016-06-24
US201662419736P 2016-11-09 2016-11-09
PCT/US2017/039300 WO2017223566A1 (en) 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder

Publications (1)

Publication Number Publication Date
MX2018015985A true MX2018015985A (es) 2019-09-13

Family

ID=60784803

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015985A MX2018015985A (es) 2016-06-24 2017-06-26 Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.
MX2022013671A MX2022013671A (es) 2016-06-24 2018-12-18 Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013671A MX2022013671A (es) 2016-06-24 2018-12-18 Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.

Country Status (13)

Country Link
US (1) US20190209464A1 (es)
EP (1) EP3474842A4 (es)
JP (2) JP2019520361A (es)
KR (2) KR102634829B1 (es)
CN (1) CN109789122A (es)
AU (2) AU2017281941A1 (es)
CA (1) CA3028731A1 (es)
MX (2) MX2018015985A (es)
NZ (1) NZ750067A (es)
PH (1) PH12018502738A1 (es)
RU (2) RU2767062C2 (es)
SG (2) SG10202013034QA (es)
WO (1) WO2017223566A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12290596B2 (en) 2021-08-04 2025-05-06 Indivior Uk Limited Compositions and methods for the treatment of opioid overdose

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767062C2 (ru) * 2016-06-24 2022-03-16 Опиант Фармасьютикалз, Инк. Составы, устройства и способы для лечения алкогольной зависимости
EP3538189A4 (en) * 2016-11-09 2020-04-22 Opiant Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF CONDITIONS MEDIATED BY AN OPIOID RECEPTOR
WO2018093666A1 (en) * 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
US20210220346A1 (en) * 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
WO2020132263A1 (en) * 2018-12-20 2020-06-25 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders
EP3946547A4 (en) 2019-03-26 2023-01-18 Pocket Naloxone Corp. DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
BR112021021841A2 (pt) * 2019-05-16 2022-01-04 Shin Nippon Biomedical Laboratories Ltd Formulação de pó para administração intranasal, e método de fabricação da mesma
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
CN118984699A (zh) * 2022-01-26 2024-11-19 图莱克斯制药公司 新的组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5069895A (en) * 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
EP0444778A1 (en) * 1990-02-14 1991-09-04 Alcon Laboratories, Inc. Use of alkyl saccharides to enhance the penetration of drugs
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
US9895444B2 (en) * 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
JP5437236B2 (ja) * 2008-04-16 2014-03-12 一般財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
UA111342C2 (uk) * 2010-10-29 2016-04-25 Троікаа Фармасьютікалс Лімітед Назальні композиції вітаміну b12
CA2835940C (en) * 2011-05-13 2020-08-04 Euro-Celtique S.A. Intranasal pharmaceutical dosage forms comprising naloxone
US10485798B2 (en) * 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140171458A1 (en) * 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
DE202013105715U1 (de) * 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US9480644B2 (en) * 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
RU2767062C2 (ru) 2016-06-24 2022-03-16 Опиант Фармасьютикалз, Инк. Составы, устройства и способы для лечения алкогольной зависимости

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12290596B2 (en) 2021-08-04 2025-05-06 Indivior Uk Limited Compositions and methods for the treatment of opioid overdose

Also Published As

Publication number Publication date
EP3474842A1 (en) 2019-05-01
RU2022103366A (ru) 2022-03-01
MX2022013671A (es) 2022-12-13
JP2022088592A (ja) 2022-06-14
EP3474842A4 (en) 2020-01-29
CA3028731A1 (en) 2017-12-28
AU2017281941A1 (en) 2019-02-07
WO2017223566A1 (en) 2017-12-28
RU2767062C2 (ru) 2022-03-16
AU2023202420A1 (en) 2023-05-11
KR20220167279A (ko) 2022-12-20
KR20190055057A (ko) 2019-05-22
PH12018502738A1 (en) 2019-10-21
RU2019101810A (ru) 2020-07-27
KR102453781B1 (ko) 2022-10-12
JP7492548B2 (ja) 2024-05-29
KR102634829B1 (ko) 2024-02-07
SG11201811580SA (en) 2019-01-30
RU2019101810A3 (es) 2020-10-14
CN109789122A (zh) 2019-05-21
US20190209464A1 (en) 2019-07-11
NZ750067A (en) 2025-11-28
JP2019520361A (ja) 2019-07-18
SG10202013034QA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2018015985A (es) Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2022002141A (es) Aparatos, sistemas y metodos de entrega de semillas.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
ES2631504R1 (es) Medicamentos de administración nasal y métodos para su uso
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
DK3703785T3 (da) Lægemiddelindgivelsesanordning
MX386826B (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
IL291521A (en) An injection device, especially an automatic injector, for the simultaneous administration of several drugs
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
MX2016013236A (es) Formulacion inmunosupresora.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
EP3597235A4 (en) MEDICINAL LIQUID INJECTION DEVICE
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
UY35750A (es) Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b
MX384447B (es) Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
DK3681564T3 (da) Lægemiddeladministrationsanordning
CL2016002653A1 (es) Combinación farmacéutica que comprende brexpiprazol y nalmefeno; composición farmacéutica que los comprende; kit farmacéutico; y uso de la combinación para la prevención y tratamiento de un trastorno relacionado con sustancias como el alcohol.
UY35622A (es) Moduladores de los receptores de estrógeno y sus usos